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Introduction
Before the GWAS (genome-wide association study) era, many genetic determinants of
disease were found via analysis of multiplex pedigrees, that is, by looking for genetic
markers that run in families in a similar way as disease. GWAS advent has robbed pedigree
analysis of its luster. Future scientific methodology seesaw might bring pedigree analysis
back into the spotlight.
After the recent discovery of hundreds of disease-associated variants, interest is focusing
on the way these variants affect downstream molecular markers, such as transcripts and
protein levels, and on the way the resulting changes in these markers in turn affect disease
risk. Statistical methods such as Mendelian Randomization [20], hereafter denoted as
MR, represent important tools in this effort. Most MR studies are based on data from
unrelated individuals, a notable exception being [6]. In the present paper we argue that by
enriching these data with data from family-related individuals, a number of difficulties that
are encountered in MR can be significantly attenuated.
Motivated by the above considerations, this paper discusses extensions of MR to deal
with pedigree data. We adopt the Bayesian MR framework proposed by Berzuini and
colleagues [5], and extend it in various ways to deal with pedigree data. The proposed
method exploits recent developments in Markov chain Monte Carlo (MCMC) inference, as
offered by the Stan probabilistic programming language [7].
We illustrate the method with the aid of data generated by ImmunoChip genotyping and
transcriptome/protein assays on members of Multiple Sclerosis (MS) multiplex pedigrees
from an isolated Sardinian (italian island) population. With this kind of data, environmental
confounding and population stratification are expected to have less impact on causal effect
estimates, and the effects of rare variants to be easier to detect. Thanks to our Bayesian
technology, we perform a ”clever” analysis where an initial model is gradually elaborated
to bring biological theory and relevant information in general to bear. In this paper, we
include in the MR model such information as a family indicator, parental protein levels and
kinship. Not only do such enhancements provide extra protection against bias, but they also
allow us to explore a number of secondary aspects of the biological mechanism. A further
advantage of the Bayesian approach is the simple way it deals with incomplete information.
In our study, missing values of the exposure (the level of a protein) are treated as additional
parameters to be estimated from the data, without incurring biases, as is natural in Bayesian
analysis.
The ”outcome” variable of our analysis is the MS disease indicator. MS lends itself well to
a MR study. This disease tends to become manifest early during reproductive lifespan of
most humans, throughout history, and is therefore likely to have a strong genetic component.
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Genetic variants are therefore expected to act as good instruments for the MR analysis.
The main scientific question in this paper is whether the plasma level of IL12A protein
(which in our analysis will be referred to as the ”exposure”) is causal with respect to
development of MS (outcome). It is believed that dysregulation of circulating proteins
is a causal determinant in many pathologies, more directly so than genetic variants. Our
analysis is further motivated by the importance of proteins as natural drug targets. We
could have harnessed publicly available eQTL information to involve in the analysis protein
concentrations in tissues other than blood, but we do not pursue this here, not to obscure
the main points of the paper, whose main message is methodological.
Methods
Sample Description
Our MS patients were ascertained through the case register established in 1995 in the
province of Nuoro, Sardinia, Italy. Cases were diagnosed according to Poser’s criteria [30].
Twenty extended MS multiplex pedigrees were selected for the analysis, for a total of
N = 936 individuals (98 cases and 838 unaffected relatives). A subset of the pedigree
members had complete data, consisting of the observed levels of the IL12A protein (the
exposure), the known disease indicator (the outcome variable), and the genotypes at all
loci of Immunochip (see below). The remaining individuals had complete data except for a
missing value for the protein level.
Genotyping Data
Genotyping data were obtained by using Immunochip Illumina Infinium HD custom
array (hereafter “Immunochip” for brevity), designed for fine mapping of 184 established
autoimmune loci [4].
The quality control-filtered dataset included 127134 Single Nucleotide Polymorphisms
(SNPs) across Immunochip [15]. For a first stage of our analysis, we imposed a maximum
correlation of r2 = 0.20 between candidate instrumental SNPs within a 100 Kb window, by
using the indep-pairwise command of the PLINK package [1]. This yielded a total
of 19121 candidate SNP instruments across Immunochip.
3
Protein Selection and Profiling
The protein we chose for our illustrative study was IL12A. Choice was made prior to
considering the data, on the basis of Genome-Wide Significant (GWS) association between
MS and genetic variants located within (e.g. exonic, intronic, in the UTR) or in the proximity
(e.g. downstream, intergenic) of the protein-coding gene [4] and on the basis of literature
evidence on the biological role of this cytokine in the context of MS [10] [19] [31] [36].
Detailed information about the locations of the strongest MS association signals within or
in the proximity of the protein-coding genes, and about the strengths of the MS associations,
are reported for IL12A in the Supplementary Material.
Plasma profiles were analysed by using a bead-based antibody array format, consisting
of polyclonal Human Protein Atlas [26] antibodies immobilized onto microspheres in
suspension [33] [32] (see Supplementary Material for details).
Selection of Instrumental Variants
Genetic variants with a significant marginal association (p < 5× 10−3) with the level of
the protein of interest and mutual r2 < 0.20 correlation were selected to act as instrumental
variables (IVs) in the first stage of our analysis. The liberal p < 5 × 10−3 threshold is
justified by the fine genotyping of candidate gene regions and by recent arguments [38] [18]
in favour of using sub-genome-wide-significance loci to strengthen biologically interesting
signals. It is also justified by the relative ability of our Bayesian MR method (when
compared with most frequentist approaches) to deal with the weak instrument bias, thanks
to the uncertainty of the estimated exposure coefficients being explicitly included in the
model.
Notation
In our analysis, the putative causal factor (with respect to disease) is the circulating level
of protein IL12A. We call this variable the ”exposure”, and denote it as X . We let the
symbol ΣX denote a regime indicator [13] [14] which tells us whether we are considering
the actual data generating regime for X , which is observational, or a hypothetical regime
where variable X in each individual is set to a value x by intervention. The observational
regime corresponds to ΣX = ∅, whereas the latter, interventional, regime corresponds to
ΣX = x. In our analysis the outcome variable, Y , indicates whether the individual has
the disease (Y = 1) or not (Y = 0). We are interested in the ”causal effect” of X on Y ,
that is, in the way the distribution of Y changes when X is first set by intervention to a
reference value x0 and then forced to take the new value x1. Throughout this paper we take
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this causal effect to be defined as the causal odds ratio (COR):
COR =
P (Y = 1 | ΣX = x1)
P (Y = 1 | ΣX = x0)
1− P (Y = 1 | ΣX = x0)
1− P (Y = 1 | ΣX = x1) (1)
The reason why we can’t generally measure causal effect by standard regression of Y
on X is that the regression coefficient will have no causal interpretation in the presence
of unobserved confounders of the exposure-outcome relationship, which we denote as
U . This is, indeed, why we need to use MR. We shall model U as an individual-level
scalar variable, more precisely, a one-dimensional reduction of the unknown collection of
confounders. MR requires availability of a set of instrumental variables, or instruments,
denoted as Z ≡ (Z1, . . . , ZJ), which in a standard analysis will often correspond to the
individual’s genotypes at a set of SNP loci. Each of these genotypes we code as ”allele
doses”, with values (0, 1, 2) respectively indicating presence of zero, one and two copies
of the ”alternative” allele at the locus. For most individuals in the pedigree, we also have
observed (i) maternal and paternal genotypes at each instrumental locus and (ii) the levels of
protein IL12A in the father and in the mother. Let the collection of maternal (rep., paternal)
genotypes for the generic individual be denoted as Zm (Zp). Let the protein levels for the
mother and the father of the generic individual be denoted as WMand WF , respectively .
We further introduce an individual-level categorical variable, denoted as F , which indicates
the individual’s pedigree of membership, or family. Further notation will be introduced in
the next sections, as required.
Assumptions
This paper uses Dawid’s conditional independence formalism [12], with the ⊥⊥ symbol
representing conditional independence, so that A⊥⊥B | C, stands for “A is independent
of B given C, and A 6⊥⊥B, means “A is not independent of B ”. Conditions introduced in
this section are required for method validity, except for one of them. They are essentially
identical to those required by standard MR methods.
Here are the assumptions. Each jth instrumental variable, Zj , must satisfy the confounder in-
dependence condition Zj ⊥⊥U , stating that the instrument is unrelated to exposure-outcome
confounders. A further condition called exclusion-restriction requires that Y ⊥⊥Zj | (X,U),
that is, each jth instrument can be associated with response only via the exposure. Exclusion-
restriction is a desirable condition, however, unlike the remaining conditions in this section,
it is not required by our method. Next comes the instrument relevance condition, Zj 6⊥⊥X ,
stating that no instrument is independent of the exposure. We have also conditions involving
the regime indicator, ΣX . The confounder invariance condition, U ⊥⊥ΣX , requires that
the distribution of the confounders U be the same, whether or not we intervene on X ,
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and regardless of the value imposed on or observed in X . Next comes the interventional
irrelevance condition ΣX ⊥⊥Z, requiring that any intervention on X has no consequence
on Z, and the interventional modularity condition, ΣX ⊥⊥Y | (X,U), asserting that once
we are told the values of X and U , the distribution of Y no longer depends on the way the
value of X has arisen, whether observationally or through the intervention of interest.
Those independence relationships that involve the (non-stochastic) regime indicator should
be interpreted in the light of the extended conditional independence calculus described by
Constantinou et al [11]. The relationships between ΣX and the remaining variables, as
depicted in Figure 1, characterize the influence of X on Y , corresponding to the X → Y
arrow, as causal. The remaining arrows in the graph, eg Z → X , do not necessarily have to
be interpreted as causal, which greatly expands method applicability.
How realistic are the above assumptions? This is a crucial question, considering that
all the above assumptions, except for instrumental relevance, are at best only indirectly
testable, or corroborated on the basis of bological knowledge. Take, for example, the
confounder independence assumption. In our application, where the exposure is a low-level
biological mark, it may be reasonable to assume that those genetic variants that operate
in cis with respect to the studied protein, exert no effect on common causal precursors of
exposure and outcome other than effects mediated by the exposure. This assumption can
be further corroborated by investigations based on eQTL data and on the known linkage
disequilibrium (LD) pattern in the DNA region of interest. The assumption of confounder
invariance requires more attention than is usually the case. In our application, for example, if
the intervention represented by ΣX consisted of a particular diet, then confounder invariance
would be violated, because a diet will hardly modify the level of the protein without altering
a constellation of metabolites that act as potential confounders. Interventional irrelevance
is defendable in our applicative situation, by using randomization arguments. As concerns
interventional modularity, in our study this condition implies, in particular, that a unit
increase in X caused by one of the variants in the instrumental set should exert on Y the
same effect as a unit increase in X caused by the intervention of interest. In our application,
where the instrumental effects are regulatory and the intervention of interest consists of a
pharmacological modification of X , interventional modularity appears to be a defendable
assumption.
All the conditions defined above, except for exclusion-restriction, are required by our
method.
Sometimes it is possible, and then helpful, to represent the qualitative structure of a
statistical model by a directed acyclic graph [22]. A stripped-down representation of the
class of MR models discussed in the present paper is shown in Figure 1. All the conditions
stated above (except for exclusion-restriction) can be read off the graph of Figure 1 by
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applying d-separation [17] or moralization [22], with the following additional rules: (i)
faithfulness [34] of the Z → X edges (which means assuming that any distribution which
follows the model only exhibits independence relations represented by the directed acyclic
graph), and (ii) assigning a value x to ΣX implies the simultaneous assignment of the same
value to X , and (iii) assigning a value x to ΣX implies that all arrows into X except for
ΣX → X are severed. Because most of the conditions introduced at the beginning of this
section are not directly testable on the basis of the data, the Reader should be aware that
graphs like the one shown in Figure 1 describe an assumed, ultimately uncertified, albeit
plausible, state of affairs. We shall assume throughout the paper that the above described
conditions, bar exclusion-restriction, are valid.
We conclude this section with a brief discussion of the exclusion-restriction assumption.
This assumption (which is not required by our method) does not allow an instrument to
exert an effect on Y other than that exerted though the mediating effect of X . In our graph
of Figure 1, this condition is violated by the ZJ → Y arrow. Because of this, the effect
of instrument ZJ on Y is said to be “pleiotropic ” according to Figure 1. In the context
of our application, pleiotropic effects may arise from two broad classes of mechanism.
The first is due to the eQTL variants used as instruments being in linkage disequilibrium
(LD) with eQTLs of nearby genes. The second is due to the instrumental variant exerting
a causal effect on Y through a pathway independent of X . Although the former type of
pleiotropy could, in principle, be neutralized by conditioning on the eQTLs in the region,
except for the instrumental variants, the latter cannot be directly tested from the data. It
would therefore be uncautious to perform MR by using a method that does not allow for
general types of pleiotropy. Our Bayesian approach deals with the problem by explicitly
introducing the unknown pleiotropic effects in the model, and by treating them as unknown
parameters to be estimated from the data.
Progressive Elaboration of the Model
A ”naive” approach consists of analyzing the pedigree data by using the Bayesian MR
model proposed by Berzuini and colleagues, as described in [5], as if the individuals
were independent. This will, of course, produce biased estimates. We shall use this
”independence model” in a preliminary analysis of the data. We shall then step through a
sequence of re-analyses of the data based on more elaborated, and more realistic, models,
that we describe in the following.
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Figure 1: Graphical representation of a Mendelian randomization model for the analysis of unrelated
individuals.
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Independence Model
The model of Berzuini and colleagues [5] assumes that individuals are independent, and
that the X variable has been standardized to have zero mean and unit standard deviation.
The data generating equations of the model conform with the conditional independence
assumptions expressed in Figure 1, and take the form:
P (U) = N(0, 1), (2)
P (X | Z1, . . . , ZJ , U) = N(
J∑
j=1
αjZj + δXU, σ
2
X), (3)
P (Y | X,Z1, . . . , ZJ , U) = logit−1(ωY + θX +
J∑
j=1
βjZj + U), (4)
where N(a, b) stands for a normal distribution with mean a and variance b, the symbol
α ≡ (α1, . . . , αJ) denotes the instrument (i)-exposure (e) associations and β ≡ (β1, . . . , βJ)
are the pleiotropic effects. The only difference from Berzuini et al here is that the outcome
variable Y is no longer normal, but Bernoulli, as appropriate for a binary random variable.
Recall that, in our study, some components of the X vector (protein level measurements)
are missing, which is not made explicit in the notation. The Bayesian inference engine
identifies the missing components and treats them as unknown parameters, effectively
integrating them out to obtain the posterior distribution for the parameters of inferential
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interest. Note that this way of dealing with missing data is more efficient than, say, imputing
each missing component of X on the basis of the individual’s observed Z values, thanks to
the fact that, in our method, the missing values are estimated by using information about
both X and Y .
In the above equations, the causal effect of interest, denoted as θ, represents the change
in log-odds of probability of Y = 1 caused by an interventional change of one standard
deviation in X .
As shown in [5] for the normal case, parameters (α, τX) are identified by the data, but
the remaining parameters, including the causal effect of interest, θ, are not. Berzuini and
colleagues deal with the problem by a combination of two devices. The first consists of
introducing the additional (untestable) assumption that each jth component of β is a priori
independent of the remaining parameters of the model, formally, P (βj | αj, τX) = P (βj).
This is called the Instrument Effects Orthogonality (IEO) condition. The second consists of
introducing a proper, scientifically plausible, prior for β, which makes inferences possible by
inducing on θ (and on further parameters of potential posterior interest) a proper posterior.
As concerns the prior component of our Bayesian model, we invite the Reader to consult [5].
Variations have been introduced. While still imposing on the pleiotropic effects β a
horseshoe prior [8], we are now using the enhanced version of this distribution proposed by
Piironen and Vehtari [28]. Also, we take θ – the causal effect of main inferential interest
– to have a Cauchy(0,2.5) prior, with the following justification. Because X has been
standardized to have mean 0 and unit standard deviation (SD), the mentioned prior for θ
states as unlikely that a one-SD change in protein level causes a change in risk of disease
exceeding 5 points on a logit scale, which corresponds to shifting a probability of disease
occurrence from, say, 0.01, to 0.5, or from 0.5 to 0.99. This is also in agreement with
current evidence on the effect of circulating proteins on disease [35].
Finally, we are now taking the i-e associations, α, to be independently distributed according
to a double-exponential distribution with mean 0 and unknown scale. One merit of this
prior is to shrink the small effects to zero, which reduces the weak instrument bias, so that
the model works with an adaptively selected subset of strong instruments.
Introducing Kinship
Treating members of a pedigree as independent individuals, which they are not, will
produce overconfident and biased estimates. We remedy this by introducing in the model
between-individual correlation in the form of the kinship matrix, which can be derived
by a standard algorithm from the structure of the pedigree. We are currently working
with a single, overarching, kinship matrix of size N × N , where N is the total number
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of individuals in the sample. This large matrix contains zeros corresponding to pairs of
individuals in different families. The method could be made computationally more efficient
by introducing family-specific matrices. Kinship information is introduced in the model by
writing:
P (Y | X,Z1, . . . , ZJ , U) = Bernoulli(pi), (5)
logit(pi) = MVN(µ,Σ), (6)
µ = ωY + θX +
J∑
j=1
βjZj + U, (7)
where Σ is the N × N kinship matrix, the notation MVN(a, b) stands for multivariate
normal distribution with vector mean a and variance-covariance matrix b.
Introducing Family Effects
In our analysis, we incorporate family information simply by designating a categorical
variable F to indicate the individual’s family, with F ∈ (1, . . . ,M), with M = 12, and by
modifying the outcome and exposure models to take the following form:
P (X | Z1, . . . , ZJ , U, F ) = N(ν, σ2X),
ν =
J∑
j=1
αjZj + δXU +
M∑
f=1
IF=f γ
X
f ,
P (Y | X,Z1, . . . , ZJ , U, F ) = Bernoulli(pi),
logit(pi) = MVN(µ,Σ),
µ = ωY + θX +
J∑
j=1
βjZj + U +
M∑
f=1
IF=f γ
Y
f ,
where IA stands for the indicator function, taking value 1 if the logical condition A is true,
and value 0 otherwise. The quantities γX ≡ (γX1 , . . . , γXM) and γY ≡ (γY1 , . . . , γYM) are
vectors of unknown ”family effects”, respectively on X and on Y . In our analysis, we
have imposed on these parameters independent and mildly informative priors, with greater
spread than the prior for θ.
The family indicator appears in the graph of Figure 2 with the symbol F . According to
this graph, failure to condition on this indicator (that is, removing the F variable from
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Figure 2: Incorporating a family indicator variable (F ).
unobserved
U
Family
indicator
F
protein
level
X
affected by
disease?
Y
instrumental
genotypes
Z
the model) ”opens” (unblocks) the Z ← F → Y path, and the Z ← F → U path, in the
terminology of d-separation. Which means that failure to condition on family creates a
spurious, exposure-unmediated, association between instrument and outcome and, what’s
even worse, violates the Confounder Independence assumptions. Hence, inclusion of
the family indicator in the model prevents the estimate of the causal effect from being
unduly distorted. In situations where the sample contains unrelated (in addition to related)
individuals, the unrelateds may be lumped into a single, notional, family.
Introducing Parental Protein Information
In this final elaboration step of the model we introduce information about the measured
level of protein in the individual’s parents. This is motivated by the assumption that there
are unobserved loci in DNA, denoted by Z ′, that (individully or collectively) have an effect
on the protein of interest. The individual’s protein level becomes associated with that of
their parents through Z ′. And, because of this, parental protein level become additional
candidate instruments in the analysis. We incorporate parental protein information simply
by designating the continuous variables PM and PF to represent the measured level of
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circulating IL12A protein in the individual’s mother and father, respectively, after standard-
izing them to have zero mean and unit variance. The two variables are incorporated in the
exposure model by writing:
P (X | Z1, . . . , ZJ , U, F, PM , PF ) = N(ν, σ2X),
ν =
J∑
j=1
αjZj + δXU +
M∑
f=1
IF=f γ
X
f + α
MPMα
FPF
with αM and αF to be estimated from the data. It can be shown (but this is outside the
scope of the present work) that the modification is valid provided we assume that Z and Z ′
are not correlated, and that Z ′ does not influence Y other than through changes in X .
Results
Results from Initial Model
Estimates of the causal effect of the circulating level of IL12A on risk of MS were ob-
tained by using R package MendelianRandomization [39], as found on http://cran.r-
project.org. The frequentist causal effect estimates, expressed on a log-odds-ratio scale
with their corresponding 95% confidence intervals, are summarised in Table 1. Difficulties
introduced by the missing IL12A values have been sidestepped in the simplest way: by
discarding individuals who had a missing IL12A value when calculating the i-e associations.
According to Table 1, estimates from the frequentist MR methods considered in this paper
exhibit a poor consistency. A significant estimate of the causal effect was obtained only
with the Simple Median and with the Penalized IVW methods, the latter requiring the
assumption of no pleiotropy.
The model by Berzuini and colleagues [5], which also assumes sample individuals to be
independent of each other (see Methods section), gave an estimated log-odds-ratio causal
effect of -0.202, with a standard error of 0.078, and a 95% credible interval of -0.418
through -0.091. This result was obtained by treating the missing protein levels as additional
unknown parameters to be estimated from the data.
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Method Estimate Std Error 95% confidence interval P-value
1 Simple median -0.30 0.15 -0.59 -0.02 0.04
2 Weighted median -0.07 0.14 -0.34 0.20 0.61
3 Penalized weighted median -0.15 0.14 -0.42 0.12 0.28
4 IVW -0.14 0.09 -0.33 0.04 0.12
5 Penalized IVW -0.21 0.10 -0.40 -0.02 0.03
6 Robust IVW -0.21 0.12 -0.44 0.02 0.08
7 Penalized robust IVW -0.23 0.10 -0.42 -0.04 0.02
8 MR-Egger 0.51 0.37 -0.22 1.25 0.17
9 Penalized MR-Egger 0.51 0.37 -0.22 1.25 0.17
10 Robust MR-Egger 0.51 1.01 -1.48 2.50 0.61
11 Penalized robust MR-Egger 0.51 1.01 -1.48 2.50 0.61
Table 1: Estimates for the causal effect of the circulating level of IL12A on risk of MS obtained by using
R package Mendelian (http://cran.r-project.org). Estimated causal effects are expressed on a
log-odds-ratio scale.
Results after Introducing Kinship
Our frequentist analyses were repeated in a sounder fashion, by estimating the disease-
instrument log-odds-ratio associations via a mixed-effects model (lmekin function of
R, as described in [29]), that allows family relationships between pedigree members, as
expressed by the kinship matrix, to be taken into account [15]. Significant estimates were
then obtained by using IVW (θˆ = −0.18, p < 0.0001) and WME (θˆ = −0.11, p = 0.012),
but not by using MR-ER (θˆ = −0.23, p = 0.7).
By contrast, when we extended the model by Berzuini and colleagues to incorporate family
relationships, as expressed by the kinship matrix (see Methods section), and used it to
re-analyse the data, the estimated causal effect was no longer significant, as reported in
Table 2. This was not unexpected, when one considers that between-individual correlation
reduces the ”effective” sample size, and, as a consequence, statistical power.
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PERCENTILES OF POSTERIOR
CAUSAL EFFECT OF 1SD CHANGE DISTRIBUTION
IN PROTEIN LEVEL ON MS RISK 5 25 50 75 95
Causal Log Odds Ratio Effect -0.91 -0.59 -0.39 -0.17 0.10
Causal Odds Ratio Effect 0.4 0.55 0.67 0.84 1.1
Table 2: Estimates for the causal effect of the circulating level of IL12A on risk of MS obtained by using an
extension of the model by Berzuini and colleagues which incorporates family relationships, as expressed by
the kinship matrix.
Results after Introducing Family Effects
In the Methods section we have seen that(pedigree) membership may introduce bias in the
estimated causal effect by acting as a confounder of the relationship between instrumental
genotypes and outcome, in a way similar to what population stratification does. This is a
consequence of the family variable being generally associated with both the individual’s
genetic set-up and with disease-linked unobserved factors (genetic variants, environment,
education, and so on). See the Methods section for a more rigorous discussion of the
issue. When we introduced both kinship information and the family variable (as a 12-level
categorical factor) in the model, we got the causal effect estimate summarised in Table 3.
PERCENTILES OF POSTERIOR
CAUSAL EFFECT OF 1SD CHANGE DISTRIBUTION
IN PROTEIN LEVEL ON MS RISK 5 25 50 75 95
Causal Exposure Log Odds Ratio -1.05 -0.69 -0.43 -0.19 0.14
Causal Exposure Odds Ratio 0.35 0.50 0.65 0.82 1.15
Table 3: Estimated causal effect of IL12A protein level on MS, expressed on both a log-odds ratio and
an odds ratio scale, as obtained by an analysis that incorporates both kinship information and the family
indicator.
A comparison with the preceding table shows that introduction of the family variable left
the point estimate of the causal effect substantially unchanged, while widening the credible
interval, with a consequent, further, reduction in statistical significance of the result. This is
hardly suprising, when one considers that families 3 and 7 (out of our 12 families) impacted
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on both exposure and outcome with effects of the same sign, as described later in this
section. This will inevitably inflate association between exposure and outcome beyond the
component of association due to a genuinely causal relationship.
Results from Final Model
In addition to kinship and to the family indicator, our final model includes the measured
parental levels of circulating IL12A protein, which means the protein level in the mother and
in the father. See Methods section for technical details. This final elaboration increased the
amount of instrumental information in the model, and produced the estimates summarized
in Table 4. The point estimate for the causal effect of IL12A protein level on risk of MS
was -0.49 on a log-odds ratio scale, and 0.61 on an odds-ratio scale. The corresponding
95% credible interval, also reported in Table 4, was entirely contained in the negative real
axis, and included effect values of biological importance.
PERCENTILES OF POSTERIOR
CAUSAL EFFECT OF 1SD CHANGE DISTRIBUTION
IN PROTEIN LEVEL ON MS RISK 5 25 50 75 95
Causal Log Odds Ratio Effect of Exposure on Outcome -1.12 -0.71 -0.49 -0.29 -0.1
Causal Odds Ratio Effect of Exposure on Outcome 0.33 0.49 0.61 0.75 0.90
Table 4: Causal effect estimates from a model that incorporates kinship information, family indicator, and
parental protein levels.
Figures 3 through 5 summarize extra output of the analysis via our final model. These
figures have been obtained by using the excellent bayesplot package, writen in R
language by Jonah Gabry and colleagues [16], as an aid to studying the output of Stan
analyses.
Figure 3 shows posterior intervals of for the instrument-exposure associations, α. It is
apparent from the figure that a few instruments, eg. instrument 49, stand out in terms
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of strength. The sparsity prior we have imposed on these effects is able to pick up the
few ”needles in the haystack”, while downplaying the role of weaker instruments, at the
same time working in the direction of a reduction of the weak instrument bias. It might be
interesting to investigate the strong instruments from a functional point of view.
Figure 4 shows posterior intervals for familial effects on outcome, that we call ”direct”
because they are not mediated by the exposure. One may wish to interpret these as familial
effects mediated by IL12A-independent pathways, environment and lifestyle. The figure
highlights some families (eg., family 12) as characterized by a higher risk of MS, compared
with the others. In a separate work we investigate the factors responsible of such differences
in detail. Other families (eg., family 2) appear to ”protected” from MS due to factors other
than IL12A.
Figure 5 shows posterior intervals for familial effects on outcome, that we call ”indirect”
because they are mediated by the exposure. They are calculated by including in the model
a parameter defined to represent the product of the F → X effect and the X → Y effect.
The posterior distribution for this parameter gets sampled by the MCMC inference engine.
The sample are then automatically used to calculate posterior mean and credible interval. A
comparison between Figures 4 and 5 suggests that in certain families, eg. family 4 in our
sample, both the direct and the indirect effects operate deleteriously, whereas in others, eg.
family 7, the two effects tend to cancel each other.
We calculated posterior predictive check diagnostics based on discrepancies between (a
continuous approximation of) the observed outcome variable distribution and the corre-
sponding distribution generated from the posterior values of the unknown parameters of
this final model. No signal of model misfit has been found (see Supplementary Material).
Gene IL12A (p35), together with gene IL12B (p40), encodes Interleukin 12 (abbreviated:
IL12). IL12 is a pro-inflammatory cytokine, produced mainly by antigen presenting
cells (abbreviated: APCs). It acts as an immunological playmaker by inducing Th1 cell
differentiation from CD4+ naive T cells, interferon γ (abbreviated: IFN-γ) production
and tumor necrosis factor-alpha (abbreviated: TNF-α) from T cells and natural killer
(abbreviated: NK) cells [3]. A diagrammatic picture of the relevant pathway is shown in
Figure 6. The hypothesised causal effect of IL12A on risk of MS might be mediated by the
encoding of IL12 and the subsequent IL12-induced production of IFN-γ. In fact, IFN-γ
is a major cytokine found in MS lesions, and it has been found that its levels are greatly
increased during MS activity [23]. IL12-induced IFN-γ production is the key point in the
Th1 immune responses induction and proliferation.
Furthermore, in murine models, IL12 has been shown to induce Substance P (SP) precursor
mRNA in macrophages via STAT4 pathway [2] and NK1R expression by both IL12 and
IL18 stimulation via NFκB in T cells [37]. SP has a demonstrated role in neuroimmune,
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Figure 3: Estimated posterior intervals for the instrument-exposure associations, α, based on our analysis
with the final, complete, Bayesian model, that includes kinship information, family variable and parental
protein levels.
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autoimmune and inflammatory conditions, including MS [21,27]. But while IL12 and IL23
are pro-inflammatory cytokines, IL27 and IL35 are inhibitory cytokines. So, clearly, their
immune balance is crucial for the modulation of immune function.
Discussion
We have extended the Bayesian MR framework of Berzuini and colleagues [5] for use
in the analysis of pedigree data. MR has only rarely been applied to this class of data.
Also, MR has been most frequently applied to the study of high-level exposures, such as
as obesity [9, 25], whereas our illustrative application deals with a molecular exposure.
Some researchers appear confident that standard MR methods work equally well with
molecular exposures, such as transcripts and proteins. Our early experiences in this area do
not entirely corroborate this optimism, one reason being the intrinsic paucity of instruments
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Figure 4: Estimated direct causal effects of family membership on risk of MS, expressed on an odds-ratio
scale, based on our analysis with the final, complete, Bayesian model, that includes kinship information,
family indicator and parental protein levels.
at a molecular level. Although public bioinformatic repositories are sprawling with data,
the number of available instruments for the analysis of causality at a molecular level is
generally, and inevitably, poor due the the intrinsic nature of the studied mechanism. This
makes MR analyses extremely vulnerable to the presence of confounding, not least because
of possible, untestable, violations of the confounder independence assumption. MR analysis
of pedigree data (as opposed to samples of unrelateds) promises robustness to confounding,
and, for this reason, it presents itself as a useful tool for dealing with the information
weakness we encounter in the study of causality at a molecular level. Motivated by these
considerations, we have extended MR to work with pedigree data.
Results of our illustrative study point to the circulating level of protein IL12A as a potential
cause of MS. While unexciting from a statistical significance viewpoint, our results match
existing biological evidence. Interleukin 12 (IL12) is a pro-inflammatory cytokine, produced
mainly by Antigen Presenting Cells (APCs). IL12 is a heterodimeric cytokine encoded
by two separate genes, IL-12A (p35) and IL-12B (p40). It acts as an immunological
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Figure 5: Estimated indirect causal effects of family membership on risk of MS, expressed on an odds-ratio
scale, based on our analysis with the final, complete, Bayesian model, that includes kinship information,
family indicator and parental protein levels. We use the term ”indirect” to signify the effect on MS risk
exerted by membership to a particular family through the mediation of IL12A plasma level.
playmaker inducing Th1 cell differentiation from CD4+ naive T cells, interferon γ (IFN-γ)
production and tumor necrosis factor-alpha (TNF-α) from T cells and natural killer (NK)
cells [3, 20]. IFN-γ is a major cytokine found in MS lesions, and its levels are greatly
increased during MS activity [24]. IFN-γ production induced by IL12 is the key point in the
Th1 immune responses induction and proliferation. Furthermore, in murine models, IL-12
has been shown to induce precursor mRNA of Substance P (SP) in macrophages via STAT4
pathway (IL-12 induction of mRNA encoding substance P in murine macrophages from
the spleen and sites of inflammation [2]). In addition, both IL-12 and IL-18 stimulation
induces NK1R expression via NFkB pathway in T cells (IL-18 and IL-12 signal through the
NF-kappa B pathway to induce NK-1R expression on T cells [37]). SP has a demonstrated
role in neuroimmune, autoimmune and inflammatory conditions, including MS [27] [21].
As shown in the figure 6, while IL-12 and IL-23 are pro-inflammatory cytokines, on the
contrary IL-27 and IL-35 are inhibitory cytokines. So clearly, the immune balance of all the
cytokines involved is crucial for the modulation of immune function where compensatory
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Figure 6: IL12 family cytokines as a putative immunological link between IL12-A and MS.
mechanisms can play a strategic role, that may explain the negative sign of the causal effect
we found that is in contradiction with the expected increase of MS risk induced by IL12A.
From a statistical viewpoint, our IL12A data analysis illustrates a few important points.
Firstly, because introduction of kinship information in the model accounts for the reduction
in the number of ”effective” individuals due to family correlation, it may result in an
increased posterior uncertainty about the causal effect, with a reduction of evidence against
the null causal hypothesis. Introduction of the family indicator may have a similar effect
on the causal estimate, that of a greater posterior uncertainty, with a consequent further
reduction of evidence of causality. Recall that family membership is a potential instrument-
outcome confounder. The increase in posterior uncertainty consequent to introduction of
the family indicator may thus be interpreted as an effect of the de-biasing. Our results
suggest that our elaborations of the models tend to avoid over-optimistic results, which
we believe to work in the direction of a healtier science. Parental protein information,
introduced at the last model elaboration step, acted as instrumental, which resulted in an
increase of evidence of causality.
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MR has been traditionally applied to data from unrelated individuals. This is a pity, because
MR analysis of family data is inherently more robust to population stratification and
heterogeneity than analysis of untelateds. We believe this property to help disentangle
inheritable from environmental effects. A potentially fruitful idea is to collect data from
unrelated individuals and then to collect further data from the parents of those individuals,
for a joint analysis of the two data sources. Such a joint analysis can be performed via
our proposed approach by treating parent-child triads as ”families”. Or one could use
information from previous analyses of unrelateds in order to shape informative priors for
an analysis of pedigree data along our proposed lines. Pedigree analysis might prove an
invaluable tool for studying disease mechanism peculiarities of small, possibly native and
isolated, populations. We are, in particular, thinking of small populations characterized by
maverick disease patterns, that suffer from inadequate attention from the medical research
community, perhaps outside the western ”white” world.
Finally, on a more methodological note, we would emphasize the flexibility of a MCMC-
powered Bayesian approach in MR, especially thanks to the possibility of straightforward
elaboration of the basic MR model to accommodate extra relevant information and the
straightforward handling of missing information.
We are at present working on an extension of the models discussed here to incorporate
haplotype information.
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Stan code
BayesianMR <-’
data {
int<lower=0> nobs; number of individuals with non-missing value of X
int<lower=0> nmis; number of individuals with missing value of X
int<lower=0> nfam; total number of families
int<lower=0> N; total number of sample individuals (=NOBS+NMIS)
int<lower=0> J; total number of instruments
matrix[N,J] Z; matrix of standardized (mean= 0, SD= 1) values of instruments
matrix[N,N] pedigree_matrix; kinship matrix over whole sample
vector[nobs] Xobs; observed X values, transformed to a 0-mean-1-SD variables
int Y[N]; vector of (0,1) disease indicators
vector[N] PROTEINMADRE; measured protein level in mother
vector[N] PROTEINPADRE; measured protein level in father
real<lower=0> betasimsd;
real<lower=0> cauchysd;scale parameter for Cauchy prior on causal parameter
real<lower=1> nu_global; degrees of freedom for the half-t prior for tau
real<lower=1> nu_local; df half-t priors for the LAMBDAs (1→horseshoe)
matrix[N,nfam] FAM;matrix of standardized (mean= 0,SD= 1) family indicators
vector[N] muY; auxiliary
}
transformed data{
matrix[N,N] L_pedigree_matrix = cholesky_decompose(pedigree_matrix);
}
parameters {
real<lower=0,upper=1> frazionepleio; expected fraction pleiotrop. instr.
real <lower=0> sigmax; lik-unidentifiable SD of measurement error on X
real <lower=0> sigmaalpha; SD of ALPHAX hyperprior
real theta; causal effect of inferential interest
real <lower=-1,upper=1> alphaMADRE;
real <lower=-1,upper=1> alphaPADRE;
real omegay; intercept of the model for Y
real deltax; effect of U on X , and covariance betw X- and Y -errors
vector[N] u; individual-specific confounder values
vector[J] alphax; effects of instruments on exposure
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vector[nmis] Xmis; unobserved subset of values of X
vector[nfam] gammafamx;
vector[nfam] gammafamy;
vector[N] correction;
Auxiliary variables that define the global and local parameters:
vector[J] z;
real<lower=0> r1_global;
real<lower=0> r2_global;
vector<lower=0>[J] r1_local;
vector<lower=0>[J] r2_local;
}
transformed parameters {
Half-t priors for the lambdas:
vector[J] beta; unknown pleiotropic effects in real dataset
real<lower=0> tau; global shrinkage parameter
vector<lower=0>[J] lambda; local shrinkage parameter
real<lower=0> m0;
real<lower=0> scale_global;
vector[N] Xcompleto;
lambda = r1_local .* sqrt(r2_local);
tau= r1_global * sqrt(r2_global);
beta = z .* lambda*tau;
m0=floor(J*frazionepleio); expected number of large pleiotropic effects
scale_global= 2*m0/(sqrt(N)*(J-m0));
Xcompleto[1:nobs]= Xobs;
Xcompleto[(nobs+1):N] = Xmis;
}
model {
frazionepleio ˜ uniform(0.1,0.9);
z˜ normal(0,1);
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r1_local˜ normal(0.0,1.0);
r2_local˜ inv_gamma(0.5*nu_local,0.5*nu_local);
r1_global˜ normal(0.0,scale_global); required for half-t prior for TAU
r2_global˜ inv_gamma(0.5*nu_global,0.5*nu_global); as above
Model for observed values of X
Xobs ˜ normal(
FAM[1:nobs,]*gammafamx family→ X
+Z[1:nobs,]*alphax instruments→ X
+PROTEINMADRE[1:nobs]*alphaMADRE maternal protein level→ X
+PROTEINPADRE[1:nobs]*alphaPADRE
+u[1:nobs]*deltax, unknown confounder→ X
sigmax);
Model for unobserved values of X,
Xmis˜ normal( to be imputed as part of inference
FAM[(nobs+1):N,]*gammafamx+Z[(nobs+1):N,]*alphax
+PROTEINMADRE[(nobs+1):N]*alphaMADRE
+PROTEINPADRE[(nobs+1):N]*alphaPADRE
+u[(nobs+1):N]*deltax,
sigmax);
Observation model for Y
correction ˜ multi_normal_cholesky(muY, L_pedigree_matrix);
Y ˜ bernoulli_logit(omegay+Z*beta +FAM*gammafamy
+Xcompleto*theta +u +correction);
Prior
theta ˜ cauchy(0,cauchysd);
for(n in 1:N){
u[n] ˜ normal(0,1);}
alphaMADRE ˜ uniform(-1,1);
alphaPADRE ˜ uniform(-1,1);
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for(h in 1:nfam){
gammafamx[h] ˜ cauchy(0,cauchysd);
gammafamy[h] ˜ cauchy(0,cauchysd);}
for(k in 1:J){
alphax[k]˜ double_exponential(0, sigmaalpha); note 0 mean
}
}
’
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PERCENTILES OF POSTERIOR
FAMILY DISTRIBUTION OF EFFECT
5 25 50 75 95
FAMILY-SPECIFIC INDIRECT CAUSAL
EFFECT ON RISK OF MS (ODDS RATIO)
family 2 0.77 0.92 0.99 1.04 1.18
family 3 0.70 0.86 0.95 1.00 1.12
family 4 0.83 0.97 1.03 1.15 1.44
family 5 0.76 0.91 0.99 1.03 1.19
family 6 0.82 0.97 1.02 1.11 1.39
family 7 0.31 0.53 0.70 0.88 1.12
family 8 0.85 0.96 1.01 1.08 1.30
family 9 0.79 0.94 1.00 1.05 1.21
family 10 0.82 0.96 1.02 1.11 1.35
family 11 0.71 0.88 0.96 1.01 1.17
family 12 0.76 0.91 0.98 1.03 1.21
FAMILY-SPECIFIC DIRECT CAUSAL EF-
FECT ON RISK OF MS (ODDS RATIO)
family 2 0.20 0.44 0.73 1.09 1.74
family 3 0.47 0.86 1.28 1.90 3.33
family 4 0.56 1.09 1.82 3.43 10.04
family 5 0.33 0.66 1.00 1.49 2.70
family 6 0.26 0.58 0.94 1.44 2.84
family 7 0.53 0.97 1.58 2.65 5.67
family 8 0.36 0.69 1.07 1.61 3.09
family 9 0.27 0.54 0.81 1.21 2.23
family 10 0.16 0.42 0.67 1.05 1.86
family 11 0.58 1.04 1.59 2.39 4.28
family 12 0.67 1.15 1.64 2.38 4.24
Table 5: Additional results from our final model. For each of the 12 families represented in our data, this
table reports the estimated effect that being a member of that family has on MS risk, by distinguishing between
the direct and the indirect (=mediated by changes in the level of circulating IL12A protein) components of
the effect. See rigorous definition of direct and indirect effect in the Methods section.
31
